Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Mishima

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphomaYasuhito Terui, Yuji Mishima, Natsuhiko Sugimura, et al.
Clinical Biochemistry|April 12, 2015
Possible involvement of sphingomyelin in the regulation of the plasma sphingosine 1-phosphate level in human subjectsRyunosuke Ohkawa, Makoto Kurano, Yuko Mishima, et al.
International Journal of Hematology|January 18, 2026
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3Koji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
Leukemia & Lymphoma|July 9, 2025
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trialKoji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
Journal of Gastroenterology|August 26, 2006
A Japanese case of eosinophilic esophagitisKoichiro Furuta, Kyoichi Adachi, Kentaro Kowari, et al.
Leukemia|March 31, 2026
Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicityNobuhiko Yamauchi, Yuko Mishima, Tomoko Takayama, et al.
Cancer Science|May 25, 2010
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapyMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Journal of Cellular Physiology|June 18, 2002
New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IVYuji Mishima, Yasuhito Terui, Yuko Mishima, et al.
British Journal of Haematology|February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell deathYuko Mishima, Loredana Santo, Homare Eda, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphomaYasuhito Terui, Yuji Mishima, Natsuhiko Sugimura, et al.
Clinical Biochemistry|April 12, 2015
Possible involvement of sphingomyelin in the regulation of the plasma sphingosine 1-phosphate level in human subjectsRyunosuke Ohkawa, Makoto Kurano, Yuko Mishima, et al.
International Journal of Hematology|January 18, 2026
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3Koji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
Leukemia & Lymphoma|July 9, 2025
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trialKoji Izutsu, Daigo Akahane, Tomomi Toubai, et al.
Journal of Gastroenterology|August 26, 2006
A Japanese case of eosinophilic esophagitisKoichiro Furuta, Kyoichi Adachi, Kentaro Kowari, et al.
Leukemia|March 31, 2026
Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicityNobuhiko Yamauchi, Yuko Mishima, Tomoko Takayama, et al.
Cancer Science|May 25, 2010
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapyMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
Journal of Cellular Physiology|June 18, 2002
New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca2+/calmodulin-dependent protein kinase IVYuji Mishima, Yasuhito Terui, Yuko Mishima, et al.
British Journal of Haematology|February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell deathYuko Mishima, Loredana Santo, Homare Eda, et al.
Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.
Pageof 11